Anxiety Disorder
Conditions
Keywords
Anxiety, Generalized Anxiety Disorder
Brief summary
The purpose of the study is to assess the safety and effectiveness of the experimental drug, a benzodiazepine drug, in long-term use and the effects on quality of life, social and occupational functioning, sleep, and daytime sedation in subjects with anxiety disorder.
Detailed description
This trial is a long-term, open label, safety and efficacy study of an experimental medication in adults with Generalized Anxiety Disorder (GAD). To enroll in this study, investigators and patients must have first participated in Jazz Pharmaceuticals, Inc. Protocol 04-001-01. The study is designed for four stages that should last a total of 37 weeks.
Interventions
DRUGa benzodiazepine drug
Sponsors
Jazz Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Complete Study 04-001-01 * Able to take the medication for 9 months * Understand and sign the Informed Consent * Comply with all study-related procedures * Women of child bearing potential must have a confirmed negative urine pregnancy test * Lack of clinically significant abnormalities in health
Exclusion criteria
* Experienced any SAEs (serious adverse events) that were related or possibly related to study drug during participation in Study 04-001-01 * Early termination from study 04-001-01 * Any new condition that could interfere with the evaluation of the subject, interpretation of safety data, or compliance with the protocol requirements * Experiencing AEs (adverse events) such that in the opinion of the investigator, per protocol, study drug administration or safe participation in this study would be precluded. * Taken any disallowed medications noted in Study 04-001-01 between the completion of Study 04-001-01 and entry into this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment (over 37 additional weeks following the double-blind study) of the safety of the experimental drug in long-term use in subjects with Generalized Anxiety Disorder (GAD) | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate the long-term efficacy of open-label study of the experimental drug in subjects with GAD | — |
| Assessment of the long-term effects on the quality of life, social and occupational functioning, sleep, and daytime sedation in subjects with GAD | — |
Countries
United States
Outcome results
None listed